mTOR signaling in the neuropathophysiology of depression: current evidence

References

• Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci. 2001;2(5):343–351.
   PubMed Web of Science ®Google Scholar
• Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34(1):13–25.
   PubMed Web of Science ®Google Scholar
• Raue PJ, Ghesquiere AR, Bruce ML. Suicide risk in primary care: identification and management in older adults. Curr Psychiatry Rep. 2014;16(9):466.
   Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
   PubMed Web of Science ®Google Scholar
• Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov. 2004; 3(2):136–151.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894–902.
   PubMed Web of Science ®Google Scholar
• Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012;35(1):47–56.
   PubMed Web of Science ®Google Scholar
• Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007;18(5–6):391–418.
   Web of Science ®Google Scholar
• Sheline Y, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry, 2003;160(8):1516–1518.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63–77.
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990; 185(1):1–10.
   PubMed Web of Science ®Google Scholar
• Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol. 1999;375(1–3):31–40.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231:3663–3676.
   PubMed Web of Science ®Google Scholar
• Zarate CJ, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl- d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
   PubMed Web of Science ®Google Scholar
• Iadarola ND, Niciu MJ, Richards EM, et al. Ketamine and other N-methyl- d-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6(3):97–114.
   PubMed Web of Science ®Google Scholar
• Garcia LS, Comim CM, Valvassori SS, et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(3):450–455.
   Web of Science ®Google Scholar
• Réus GZ, Abelaira HM, dos Santos MA, et al. Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors. Behav Brain Res. 2013;256:451–456.
   PubMed Web of Science ®Google Scholar
• Li N, Lee BY, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964.
   PubMed Web of Science ®Google Scholar
• Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol. 2011;23:744–755.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Bockaert J, Marin P. mTOR in brain physiology and pathologies. Physiol Rev. 2015; 95(4):1157–1187.
   PubMed Web of Science ®Google Scholar
• Li CY, Li X, Liu SF, Qu WS, Wang W, Tian DS. Inhibition of mTOR pathway restrains astrocyte proliferation, migration and production of inflammatory mediators after oxygen-glucose deprivation and reoxygenation. Neurochem Int. 2015;83–84:9–18.
   Web of Science ®Google Scholar
• Dadalko OI, Siuta M, Poe A, et al. mTORC2/Rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission. J Neurosci. 2015;35:8843–8854.
   Web of Science ®Google Scholar
• Hsu WL, Chung HW, Wu CY, et al. Glutamate stimulates local protein synthesis in the axons of rat cortical neurons by activating alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and metabotropic glutamate receptors. J Biol Chem. 2015;290:20748–20760.
   Web of Science ®Google Scholar
• Koskimäki J, Matsui N, Umemori J, Rantamäki T, Castrén E. Nimodipine activates TrkB neurotrophin receptors and induces neuroplastic and neuroprotective signaling events in the mouse hippocampus and prefrontal cortex. Cell Mol Neurobiol. 2015;35(2):189–196.
   Web of Science ®Google Scholar
• Dwyer JM, Duman RS. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry. 2013;73(12):1189–1198.
   Web of Science ®Google Scholar
• Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. 2011;16(11):1068–1070.
   PubMed Web of Science ®Google Scholar
• Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology. 2013;38(11):2268–2277.
   PubMed Web of Science ®Google Scholar
• Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24:200–216.
   PubMed Web of Science ®Google Scholar
• Lu CL, Qin L, Liu HC, Candas D, Fan M, Li JJ. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition-a Warburg-reversing effect. PLoS One. 2015;10:e0121046.
   PubMed Web of Science ®Google Scholar
• Garelick MG, Kennedy BK. TOR on the brain. Exp Gerontol. 2011; 46(2–3):155–163.
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K. Mammalian target of rapamycin: hitting the bull’s-eye for neurological disorders. Oxid Med Cell Longev. 2010;3(6):374–391.
   PubMed Web of Science ®Google Scholar
• Mohindra NA, Platanias LC. Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents. Leuk Lymphoma. 2015:1–6.
   Web of Science ®Google Scholar
• Jin Y, Qu S, Tesikova M, et al. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A. 2013;110(28):E2572–E2581.
   PubMed Web of Science ®Google Scholar
• Liu D, Xing J, Trink B, Xing M. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010;127(12):2965–2973.
   PubMed Web of Science ®Google Scholar
• Molhoek KR, Brautigan DL, Slingluff CL Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med. 2005;3:39.
   PubMed Web of Science ®Google Scholar
• Swiech L, Perycz M, Malik A, Jaworski J. Role of mTOR in physiology and pathology of the nervous system. Biochim Biophys Acta. 2008;1784:116–132.
   PubMed Web of Science ®Google Scholar
• Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33:67–75.
   PubMed Web of Science ®Google Scholar
• Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. 2014;29(7):419–423.
   PubMed Web of Science ®Google Scholar
• Su ZW, Liao JY, Zhang H, et al. Postnatal high-protein diet improves learning and memory in premature rats via activation of mTOR signaling. Brain Res. 2015;1611:1–7.
   Web of Science ®Google Scholar
• Tramutola A, Triplett JC, Di Domenico F, et al. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J Neurochem. 2015;133:739–749.
   PubMed Web of Science ®Google Scholar
• Neasta J, Barak S, Hamida SB, Ron D. mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse. J Neurochem. 201 130(2):172–184.
   Web of Science ®Google Scholar
• Banko JL, Poulin F, Hou L, DeMaria CT, Sonenberg N, Klann E. The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J Neurosci. 2005;25:9581–9590.
   PubMed Web of Science ®Google Scholar
• Banko JL, Merhav M, Stern E, Sonenberg N, Rosenblum K, Klann E. Behavioral alterations in mice lacking the translation repressor 4E-BP2. Neurobiol Learn Mem. 2007;87:248–256.
   Web of Science ®Google Scholar
• Cota D, Proulx K, Smith KA, et al. Hypothalamic mTOR signaling regulates food intake. Science. 2006;312(5775):927–930.
   PubMed Web of Science ®Google Scholar
• Abelaira HM, Réus GZ, Neotti MV, Quevedo J. The role of mTOR in depression and antidepressant responses. Life Sci. 2014;101(1–2):10–14.
   Web of Science ®Google Scholar
• Maiese K. Driving neural regeneration through the mammalian target of rapamycin. Neural Regen Res. 2014;9(15):1413–1417.
   PubMed Web of Science ®Google Scholar
• Pilar-Cúellar F, Vidal R, Díaz A, et al. Signaling pathways involved in antidepressant-induced cell proliferation and synaptic plasticity. Curr Pharm Des. 2014;20(23):3776–3794.
   Web of Science ®Google Scholar
• Hill MN, Hellemans KG, Verma P, Gorzalka BB, Weinberg J. Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev. 2012;36(9):2085–2117.
   PubMed Web of Science ®Google Scholar
• Zhu W, Wang S, Liu M, et al. Glycine site N-methyl-d-aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats. J Psychiatry Neurosci. 2013;38(5):306–316.
   PubMed Web of Science ®Google Scholar
• Zhong P, Wang W, Pan B, et al. Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology. 2014;39(7):1763–1776.
   Web of Science ®Google Scholar
• Chandran A, Iyo AH, Jernigan CS, Legutko B, Austin MC, Karolewicz B. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:240–245.
   PubMed Web of Science ®Google Scholar
• Howell KR, Kutiyanawalla A, Pillai A. Long-term continuous corticosterone treatment decreases VEGF receptor-2 expression in frontal cortex. PLoS One. 2011;6(5):e20198.
   Web of Science ®Google Scholar
• Orlovsky MA, Dosenko VE, Spiga F, Skibo GG, Lightman SL. Hippocampus remodeling by chronic stress accompanied by GR, proteasome and caspase-3 overexpression. Brain Res. 2014;1593:83–94.
   PubMed Web of Science ®Google Scholar
• Feng P, Huang C. Phospholipase D-mTOR signaling is compromised in a rat model of depression. J Psychiatr Res. 2013;47(5):579–585.
   Web of Science ®Google Scholar
• Yang C, Hu YM, Zhou ZQ, Zhang GF, Yang JJ. Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci. 2013;118(1):3–8.
   PubMed Web of Science ®Google Scholar
• Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18(1):1–6.
   Web of Science ®Google Scholar
• Autry A, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91–95.
   PubMed Web of Science ®Google Scholar
• Yang C, Li WY, Yu HY, et al. Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of rapamycin in rat hippocampus and prefrontal cortex. J Biomed Biotechnol. 2012;2012:175619.
   Google Scholar
• Chiu CT, Scheuing L, Liu G, et al. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int J Neuropsychopharmacol. 2014;18(6).
   Web of Science ®Google Scholar
• Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology. 2013;230(2):291–298.
   PubMed Web of Science ®Google Scholar
• Rice ME. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci. 2000;23(5):209–216.
   PubMed Web of Science ®Google Scholar
• Ballaz S, Morales I, Rodríguez M, Obeso JA. Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons. J Neurosci Res. 2013;91(12):1609–1617.
   PubMed Web of Science ®Google Scholar
• Binfaré RW, Rosa AO, Lobato KR, Santos AR, Rodrigues AL. Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):530–540.
   Web of Science ®Google Scholar
• Moretti M, Colla A, de Oliveira Balen G, et al. Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J Psychiatr Res. 2012;46(3):331–340.
   Web of Science ®Google Scholar
• Moretti M, Budni J, Freitas AE, et al. TNF-α-induced depressive-like phenotype and p38(MAPK) activation are abolished by ascorbic acid treatment. Eur Neuropsychopharmacol. 2015;25(6):902–912.
   Web of Science ®Google Scholar
• Amr M, El-Mogy A, Shams T, Vieira K, Lakhan SE. Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Nutr J. 2013;12:31.
   PubMed Web of Science ®Google Scholar
• Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial. Biol Psychiatry. 2002;52(4):371–374.
   Web of Science ®Google Scholar
• Moretti M, Budni J, Freitas AE, Rosa PB, Rodrigues AL. Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway. J Psychiatr Res. 2014;48:16–24.
   PubMed Web of Science ®Google Scholar
• Bettio LE, Cunha MP, Budni J, et al. Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide-cGMP and PI3K/mTOR pathways. Behav Brain Res. 2012; 234(2):137–148.
   PubMed Web of Science ®Google Scholar
• Schmidt AP, Lara DR, Souza DO. Proposal of a guanine-based purinergic system in the mammalian central nervous system. Pharmacol Ther. 2007;116(3):401–416.
   Web of Science ®Google Scholar
• Beal MF. Neuroprotective effects of creatine. Amino Acids. 2011;40(5):1305–1313.
   PubMed Web of Science ®Google Scholar
• Cunha MP, Pazini FL, Ludka FK, et al. The modulation of NMDA receptors and L-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test. Amino Acids. 2015;47(4):795–811.
   Web of Science ®Google Scholar
• Cunha MP, Budni J, Ludka FK, et al. Involvement of PI3K/Akt signaling pathway and its downstream intracellular targets in the antidepressant-like effect of creatine. Mol Neurobiol. In press 2015.
   Google Scholar
• Szewczyk B, Pochwat B, RafaŁo A, Palucha-Poniewiera A, Domin H, Nowak G. Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc. Neuropharmacology. 2015;99:517–526.
   PubMed Web of Science ®Google Scholar
• Osborn M, Rustom N, Clarke M, et al. Antidepressant-like effects of erythropoietin: a focus on behavioural and hippocampal processes. PLoS One. 2013;8(9):e72813.
   PubMed Web of Science ®Google Scholar
• Voleti B, Navarria A, Liu RJ, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74(10):742–749.
   PubMed Web of Science ®Google Scholar
• Dwyer JM, Lepack AE, Duman RS. mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int J Neuropsychopharmacol. 2012;15(4):429–434.
   Web of Science ®Google Scholar
• Koike H, Iijima M, Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology. 2011;61(8):1419–1423.
   PubMed Web of Science ®Google Scholar
• PaŁucha-Poniewiera A, Szewczyk B, Pilc A. Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology. 2014;82:59–68.
   Web of Science ®Google Scholar
• Lu Y, Wang C, Xue Z, et al. PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int J Neuropsychopharmacol. 2014;18(5).
   Web of Science ®Google Scholar
• Jernigan CS, Goswami DB, Austin MC, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(7):1774–1779.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Zanetti MV, Teixeira AL, et al. Decreased Akt1/Mtor pathway mRNA expression in short-term bipolar disorder. Eur Neuropsychopharmacol. 2015;25(4):468–473.
   Web of Science ®Google Scholar
• Yang C, Zhou ZQ, Gao ZQ, Shi JY, Yang JJ. Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol Psychiatry. 2013;73(12):e35–e36.
   PubMed Web of Science ®Google Scholar
• Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):70–75.
   PubMed Web of Science ®Google Scholar
• Karolewicz B, Szebeni K, Gilmore T, Maciag D, Stockmeier CA, Ordway GA. Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol. 2009; 12(2):143–153.
   Web of Science ®Google Scholar
• Rogers RD, Owen AM, Middleton HC, et al. Choosing between small, likely rewards and large, unlikely rewards activates inferior and orbital prefrontal cortex. J Neurosci. 1999;19(20):9029–9038.
   PubMed Web of Science ®Google Scholar
• Goswami DB, Jernigan CS, Chandran A, et al. Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:126–133.
   Web of Science ®Google Scholar
• Pizzagalli DA, Iosifescu D, Hallett LA, Ratner KG, Fava M. Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. J Psychiatr Res. 2008;43(1):76–87.
   PubMed Web of Science ®Google Scholar
• Duric V, Banasr M, Licznerski P, et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med. 2010;16(11):1328–1332.
   Web of Science ®Google Scholar
• Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem. 2001;77(3):916–928.
   PubMed Web of Science ®Google Scholar
• Jeffrey KL, Camps M, Rommel C, Mackay CR. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov. 2007;6(5):391–403.
   PubMed Web of Science ®Google Scholar
• Russo E, Citraro R, Donato G, et al. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology. 2013;69:25–36.
   PubMed Web of Science ®Google Scholar
• Cleary C, Linde JA, Hiscock KM, et al. Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull. 2008;76:469–473.
   PubMed Web of Science ®Google Scholar
• Hemmeter UM, Hemmeter-Spernal J, Krieg JC. Sleep deprivation in depression. Expert Rev Neurother. 2010;10(7):1101–1115.
   PubMed Web of Science ®Google Scholar
• Vecsey CG, Peixoto L, Choi JH, et al. Genomic analysis of sleep deprivation reveals translational regulation in the hippocampus. Physiol Genomics. 2012;44(20):981–991.
   Web of Science ®Google Scholar
• Park SW, Lee JG, Seo MK, et al. Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons. Int J Neuropsychopharmacol. 2014;17(11):1831–1846.
   PubMed Web of Science ®Google Scholar
• Opal MD, Klenotich SC, Morais M, et al. Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. Mol Psychiatry. 2014;19(10):1106–1114.
   PubMed Web of Science ®Google Scholar
• Elfving B1, Christensen T, Ratner C, Wienecke J, Klein AB. Transient activation of mTOR following forced treadmill exercise in rats. Synapse. 2013;67(9):620–625.
   Web of Science ®Google Scholar
• Mura G, Moro MF, Patten SB, Carta MG. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. CNS Spectr. 2014;19(6):496–508.
   PubMed Web of Science ®Google Scholar